RATIONALE: Lung transplantation offers the only survival option for patients with cystic fibrosis (CF) with end-stage pulmonary disease. Infection with Burkholderia species is typically considered a contraindication to transplantation in CF. However, the risks posed by different Burkholderia species on transplantation outcomes are poorly defined. OBJECTIVES: To quantify the risks of infection with Burkholderia species on survival before and after lung transplantation in patients with CF. METHODS: Multivariate Cox survival models assessed hazard ratios of infection with Burkholderia species in 1,026 lung transplant candidates and 528 lung transplant recipients. Lung allocation scores, incorporating Burkholderia infection status, were calculated for transplant candidates. MEASUREMENTS AND MAIN RESULTS: Transplant candidates infected with different Burkholderia species did not have statistically different mortality rates. Among transplant recipients infected with B. cenocepacia, only those infected with nonepidemic strains had significantly greater post-transplant mortality compared with uninfected patients (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.04-6.12; P = 0.04). Hazards were similar between uninfected transplant recipients and those infected with B. multivorans (HR, 0.66; 95% CI, 0.27-1.56; P = 0.34). Transplant recipients infected with B. gladioli had significantly greater post-transplant mortality than uninfected patients (HR, 2.23; 95% CI, 1.05-4.74; P = 0.04). Once hazards for species/strain were included, lung allocation scores of B. multivorans-infected transplant candidates were comparable to uninfected candidate scores, whereas those of candidates infected with nonepidemic B. cenocepacia or B. gladioli were lower. CONCLUSIONS: Post-transplant mortality among patients with CF infected with Burkholderia varies by infecting species. This variability should be taken into account in evaluating lung transplantation candidates.
RATIONALE: Lung transplantation offers the only survival option for patients with cystic fibrosis (CF) with end-stage pulmonary disease. Infection with Burkholderia species is typically considered a contraindication to transplantation in CF. However, the risks posed by different Burkholderia species on transplantation outcomes are poorly defined. OBJECTIVES: To quantify the risks of infection with Burkholderia species on survival before and after lung transplantation in patients with CF. METHODS: Multivariate Cox survival models assessed hazard ratios of infection with Burkholderia species in 1,026 lung transplant candidates and 528 lung transplant recipients. Lung allocation scores, incorporating Burkholderia infection status, were calculated for transplant candidates. MEASUREMENTS AND MAIN RESULTS: Transplant candidates infected with different Burkholderia species did not have statistically different mortality rates. Among transplant recipients infected with B. cenocepacia, only those infected with nonepidemic strains had significantly greater post-transplant mortality compared with uninfected patients (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.04-6.12; P = 0.04). Hazards were similar between uninfected transplant recipients and those infected with B. multivorans (HR, 0.66; 95% CI, 0.27-1.56; P = 0.34). Transplant recipients infected with B. gladioli had significantly greater post-transplant mortality than uninfected patients (HR, 2.23; 95% CI, 1.05-4.74; P = 0.04). Once hazards for species/strain were included, lung allocation scores of B. multivorans-infected transplant candidates were comparable to uninfected candidate scores, whereas those of candidates infected with nonepidemic B. cenocepacia or B. gladioli were lower. CONCLUSIONS: Post-transplant mortality among patients with CF infected with Burkholderia varies by infecting species. This variability should be taken into account in evaluating lung transplantation candidates.
Authors: Bradley S Quon; James D Reid; Patrick Wong; Pearce G Wilcox; Amin Javer; Jennifer M Wilson; Robert D Levy Journal: Can Respir J Date: 2011 Jul-Aug Impact factor: 2.409
Authors: Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma Journal: J Infect Dis Date: 2010-01-15 Impact factor: 5.226
Authors: Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn Journal: Semin Immunopathol Date: 2011-01-27 Impact factor: 9.623
Authors: Kaivon Assani; Chandra L Shrestha; Frank Robledo-Avila; Murugesan V Rajaram; Santiago Partida-Sanchez; Larry S Schlesinger; Benjamin T Kopp Journal: J Immunol Date: 2017-01-16 Impact factor: 5.422
Authors: Kay A Ramsay; Claire A Butler; Stuart Paynter; Robert S Ware; Timothy J Kidd; Claire E Wainwright; Scott C Bell Journal: J Clin Microbiol Date: 2013-09-18 Impact factor: 5.948